| |
(STEP) Ganciclovir for Cytomegalovirus (CMV Retinitis) |
 | | Ganciclovir's main toxicity is suppression of the bone marrow, while foscarnet often causes damage to the kidney and disruption of electrolyte balance. |
 | | Most clinicians have recommended initiation of therapy with ganciclovir, although there was some question of this after a trial comparing the two agents was halted early due to a survival advantage seen in people that were given foscarnet (12.6 months with foscarnet; 8.5 months with ganciclovir). |
 | | Advantages of local therapy of CMV retinitis with ganciclovir included achieving much higher concentrations of the drug in the eye where it is needed (4.1 mcg/ml with implant, 0.93 mcg/ml with intravenous), avoiding exposure of the body to the toxic effects of the drug, and avoiding use of an indwelling catheter. |
| www.aegis.com /pubs/step/1995/STEP7202.html (2043 words) |